AtriCure (NASDAQ:ATRC) Stock Gets Price Target Bump from BTIG Research

AtriCure (NASDAQ:ATRC) had its price target raised by analysts at BTIG Research from $55.00 to $63.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. BTIG Research’s target price would indicate a potential upside of 10.78% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the stock. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. Needham & Company LLC raised their price objective on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Piper Sandler upped their target price on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $54.10.

AtriCure Stock Down 0.7%

Shares of AtriCure stock opened at $56.87 on Monday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The company’s fifty day simple moving average is $51.69 and its two-hundred day simple moving average is $37.70. The company has a market cap of $2.89 billion, a P/E ratio of 270.82 and a beta of 1.24. AtriCure has a 12-month low of $25.36 and a 12-month high of $61.70.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts anticipate that AtriCure will post 0.29 EPS for the current year.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the sale, the insider owned 86,511 shares in the company, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Karl Dahlquist sold 9,370 shares of the company’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. This represents a 9.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 74,868 shares of company stock valued at $3,317,897. Company insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of AtriCure in the 2nd quarter worth about $125,198,000. Wellington Management Group LLP boosted its stake in AtriCure by 3.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock worth $97,807,000 after purchasing an additional 113,048 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in AtriCure by 8.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after purchasing an additional 75,862 shares in the last quarter. Bank of America Corp DE purchased a new stake in AtriCure during the 2nd quarter valued at about $24,465,000. Finally, Grandeur Peak Global Advisors LLC purchased a new stake in AtriCure during the 2nd quarter valued at about $16,435,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.